Sign Up
OverviewAPI
Trinity Life Sciences reports on China's 2022 NRDL update, highlighting promising pricing and access opportunities for innovative drugs with significant clinical benefit. The update includes improved negotiation success rates, a focus on innovative therapy inclusion, and a growing presence of multinational manufacturers.

Ask a question